Sabine D. Brookman-May, Professor of Urology at München University, Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared a post on X:
“Final THOR-2 results out in EU Platinum – Erdafitinib in FGFR-altered NMIBC
HR papillary NMIBC:
- Median RFS not reached vs 11.6 mo with intravesical chemo
- HR 0.25 (75% recurrence risk reduction)
HR CIS ± papillary:
- CR 94% at 8 wks | 81% at 32 wks
- Median DoR 23.3 months
Intermediate-risk NMIBC:
- CR ~89%
- Durable responses – median DoR not reached
Targeted systemic therapy showing real durability in IR and HR FGFR + NMIBC”
More posts featuring Sabine D. Brookman-May
